Bridgeline Digital: Bridgeline Announces Financial Results for the Third Quarter of Fiscal 2026

Bridgeline Digital (NASDAQ:BLIN) reported fiscal 2026 Q3 results ended June 30, 2026. The company said core product revenue grew 13% over the prior 12 months and now represents 62% of total revenue. It posted a $0.5 million net loss versus $0.8 million a year earlier. It reported 9 new customer wins and $1.7 million total contract value.

Original reporting
Published Aug 13, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$BLIN
Bullish
medium confidence
Mentioned
$BLIN
Relevance
7/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$BLINBullishMed
01

Why it matters

Investors will likely focus on whether the reported recurring revenue mix shift and new customer wins translate into improving profitability and durable ARR growth, especially ahead of the earnings call Q&A.

02

Market read

This is a company-specific earnings release with concrete operating metrics (new logos, TCV, ARR, core revenue mix) and GAAP loss figures, which can drive near-term positioning around recurring growth quality.

03

What to watch

The release emphasizes core subscription mix and ARR, but does not provide cash flow, gross margin, or detailed guidance, which are often key for re-rating small-cap SaaS/marketing tech.

Relevance 7/10Novelty 7/10Timing: after-hours earnings release and same-day 4:30 p.m. ET conference call

Background

Bridgeline Digital is an AI-powered marketing technology company focused on its HawkSearch product suite and related AI agent platform.

Company-level read

Ticker impact

$BLINBullishMedium confidence
Context

Bridgeline reported fiscal 2026 Q3 results, including net loss of $0.5M and record-tying new logo sales with $1.7M TCV.

Expected impact

Near-term bias modestly positive if investors focus on new logo traction and core subscription growth; downside risk persists if losses widen or ARR conversion disappoints.

Evidence & confidence

The article provides multiple growth and retention mix metrics (core revenue mix, new logos, ARR) plus loss figures, but lacks guidance or segment-level profitability detail to fully re-rate the business.

Market effects

Reinforces demand for AI-powered product discovery and commerce workflows, potentially supporting sentiment toward AI marketing tech peers with similar recurring revenue models.

No specific regional read-through beyond general US small-cap tech earnings sentiment.

Limited; the disclosure is company-specific with no cross-border deal or regulatory catalyst.

Counterpoint

Despite record new logo wins, the company is still loss-making, so the market may discount growth quality if operating leverage does not improve.

Key entities

  • Bridgeline Digital, Inc.

    NASDAQ-listed AI-powered marketing technology provider reporting fiscal 2026 Q3 results and product expansion in HawkSearch/Aura AI Agents.

  • Ari Kahn

    President and CEO quoted on record new logo sales and core product revenue growth.

  • Thomas Windhausen

    CFO hosting the earnings call.

Related articles

$BLINMed

Bridgeline Digital (BLIN) Q3 2026 Earnings Call Transcript

Bridgeline Digital (BLIN) reported Q3 FY2026 results on an earnings call: total revenue $3.92M vs $3.88M prior year. Subscription revenue was $3.1M (79% of total). Core product revenue grew 13% to $2.4M, with core revenue mix at 62%. Net loss was $0.5M, improved from $0.8M. Cash was $1.5M at June 30, 2026.

$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

$CDNSMed

CDNS Falls 12.9% in the Past Month. Is the Sell-Off an Opportunity?

Cadence Design Systems (CDNS) shares fell 12.9% over the past month despite Q2 results. According to the company, Q2 revenue rose 24.2% to $1.584B and non-GAAP EPS rose 27.9% to $2.11. The company raised 2026 guidance to $6.26-$6.34B revenue and $8.05-$8.15 EPS, with backlog at a record $8.1B. Valuation remains at 36.3x forward earnings.

$AIRTMedAI 8/10

Air T, Inc. Continues Track Record of Growth in First Quarter Fiscal 2027: Crestone Completes Acquisition of Arena

Air T, Inc. (NASDAQ:AIRT) reported fiscal 2027 first-quarter results for the period ended June 30, 2026. Revenue rose to $115.5 million, up 63% year over year, while operating loss widened to $12.8 million. Adjusted EBITDA was $0.8 million, down 45%. The company said results were pressured by acquisition and integration costs tied to Crestone’s Arena deal and non-cash depreciation from purchase accounting. Crestone acquired Arena Aviation Capital for $33.9 million.

$PRPOMed

Precipio, Inc. (PRPO): Results of Operations and Financial Condition

Precipio, Inc. (PRPO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623274d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, CT, Globenewswire – (Aug 14, 2026) - Specialty cancer